Table 1. Selected ongoing clinical trials for novel treatments of patients with CRPC
Agent(s)ActivityPhaseTrial ID
Targeting the AR axis
VT‐464Lyase‐selective inhibitor of CYP17I/IINCT02012920
Galeterone (TOK‐001)Dual CYP17 inhibitor and AR antagonistIINCT01709734
ARN‐509Second‐generation AR antagonistIII (SPARTAN)NCT01946204
ODM‐201Second‐generation AR antagonistIII (ARAMIS)NCT02200614
Enzalutamide + abirateroneSecond‐generation AR antagonist; CYP17 inhibitorIINCT01650194
ARN‐509 + abirateroneSecond‐generation AR antagonist; CYP17 inhibitorIbNCT01792687
Enzalutamide ± abirateroneSecond‐generation AR antagonist: CYP17 inhibitorIIINCT01949337
Targeting adaptive survival pathways
OGX‐427 + abirateroneHSP27 inhibitor; CYP17 inhibitorIINCT01681433
AT13387 + abirateroneHSP90 inhibitor; CYP17 inhibitorI/IINCT01685268
GDC‐0068 + abirateronePan AKT inhibitor; CYP17 inhibitorIb/IINCT01485861
BEZ235 + abirateroneDual PI3K and mTOR inhibitor; CYP17 inhibitorIbNCT01634061
BKM120 + abirateronePan PI3K inhibitor; CYP17 inhibitorIbNCT01634061
AZD8186PI3K beta and delta inhibitorINCT01884285
GSK2636771PI3K beta inhibitorI/IIaNCT01458067
Cabozantinib + abirateroneTyrosine kinase inhibitor; CYP17 inhibitorINCT01574937
Dasatinib ± abirateroneTyrosine kinase inhibitor; CYP17 inhibitorII (randomized)NCT01685125
Sunitinib or dasatinib ± abirateroneTyrosine kinase inhibitors; CYP17 inhibitorII (randomized)NCT01254864
Tivozanib + enzalutamideVEGF inhibitor; Second‐generation AR antagonistIINCT01885949
Dovitinib + abirateroneTyrosine kinase inhibitor; CYP17 inhibitorIINCT01994590
OGX‐011 ± cabazitaxelCLU inhibitor; microtubule inhibitorIII (AFFINITY)NCT01578655
Alisertib + abirateroneAURKA inhibitor; CYP17 inhibitorI/II (randomized)NCT01848067
Inhibiting DNA repair
OlaparibSelective PARP1 inhibitorIINCT01682772
Veliparib ± abirateronePARP inhibitorII (randomized)NCT01576172
Immunotherapy
PROSTVACIII (Prospect)NCT01322490
Targeting neuroendocrine prostate cancer
Alisertib (MLN8237)AURKA inhibitorIINCT01799278